Jubilant Pharmova Ltd.
JUBLPHARMA · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹1,505.72. Low-confidence estimate — limited data.
Piotroski F-score 3/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%6.0%
- ✕Low debt (D/E < 0.5)0.51x
- ✕Positive free cash flow
- ✓Revenue growth > 10%19%
- ✕Earnings growing-22%
- ✕Net margin ≥ 10%4.8%
- ✓Current ratio > 1.51.62
- ✓Below our fair value
- ✓Margin of safety ≥ 20%
- ✕Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✕Altman Z in safe zoneZ 2.25
- ✕Piotroski ≥ 73/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Weaknesses
- •Low return on equity (6.0%).
- •Price below its 200-day moving average (downtrend).
- •Weak Piotroski score (3/9).
Opportunities
- •Revenue growing (19% YoY).
- •Trading in our value buy zone versus sector peers.
- •Trades ~90% below our estimated fair value.
Threats
- •Earnings contracting year on year.
About Jubilant Pharmova Ltd.
Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatmen
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.